

GSK2636771

Catalog No: tcsc0747



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1372540-25-4

Formula:

$C_{22}H_{22}F_3N_3O_3$

Pathway:

PI3K/Akt/mTOR

Target:

PI3K

Purity / Grade:

>98%

Solubility:

DMSO : 10.6 mg/mL (24.46 mM; Need ultrasonic and warming)

Observed Molecular Weight:

433.42


Product Description

GSK2636771 is a potent, selective and oral inhibitor of **PI3K β** with a **K_i** of 0.89 nM and an **IC₅₀** of 5.2 nM, showing 900-fold

selectivity over p110 α and p110 γ , and 10-fold selectivity over p110 δ isoforms.

In Vitro: GSK2636771 treatment causes cell viability significantly more decreased in the control cells (p110 β -reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines) than in PTEN-mutant and PTEN wild-type EEC cells. Inhibition of p110 β by GSK2636771 or AZD6482 leads to a marked decrease of AKT phosphorylation only in the control prostate and breast cancer cell lines, whereas only marginal effects on AKT activation are observed in EEC cells^[1].

In Vivo: GSK2636771 is a p110 β inhibitor, and the p110 β primes cells for response to growth factor stimulation. While p110 β inhibition suppresses cell and tumor growth, dual targeting of p110 α/β enhances apoptosis and provides sustained tumor response in mice model^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!